Media headlines about Calithera Biosciences (NASDAQ:CALA) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.4924610954236 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- NVIDIA Corporation (NVDA) Holdings Decreased by TIAA CREF Investment Management LLC (iphonefresh.com)
- Companies to Watch as Biotech Makes a Comeback in 2017 (kait8.com)
- Companies to Watch as Biotech Makes a Comeback in 2017 … – Markets Insider (markets.businessinsider.com)
- Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : September 12, 2017 (finance.yahoo.com)
- Calithera Biosciences, Inc. (CALA)- Stocks Cheering Investors with Mouthwatering Facts – NASDAQ Times (nasdaqtimes.com)
Calithera Biosciences (NASDAQ CALA) traded up 0.64% on Wednesday, reaching $15.70. 180,553 shares of the company’s stock were exchanged. Calithera Biosciences has a 1-year low of $2.20 and a 1-year high of $20.05. The firm’s 50 day moving average is $15.10 and its 200 day moving average is $13.90. The stock’s market capitalization is $556.97 million.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.14. The business had revenue of $7.26 million during the quarter, compared to analyst estimates of $4.80 million. Analysts expect that Calithera Biosciences will post ($0.83) EPS for the current year.
A number of research firms have recently weighed in on CALA. Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. BidaskClub raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, July 7th. Wells Fargo & Company reissued an “outperform” rating and issued a $20.00 price objective (up from $15.00) on shares of Calithera Biosciences in a research note on Tuesday, June 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $19.00 price objective (up from $14.00) on shares of Calithera Biosciences in a research note on Monday, June 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $15.50.
COPYRIGHT VIOLATION WARNING: This article was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2017/09/13/calithera-biosciences-cala-earning-somewhat-positive-media-coverage-report-shows.html.
In related news, VP Keith Orford sold 2,120 shares of Calithera Biosciences stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $18.31, for a total transaction of $38,817.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 16.30% of the company’s stock.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.